Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) Sentiment Change Report

September 8, 2018 - By Robert Shackelford

Navidea Biopharmaceuticals, Inc (NYSEAMERICAN:NAVB) Logo

Sentiment for Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB)

Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) institutional sentiment increased to 0.92 in Q1 2018. Its up 0.36, from 0.56 in 2017Q4. The ratio is better, as 12 institutional investors started new and increased stock positions, while 13 cut down and sold stock positions in Navidea Biopharmaceuticals Inc. The institutional investors in our partner’s database now hold: 11.99 million shares, down from 12.03 million shares in 2017Q4. Also, the number of institutional investors holding Navidea Biopharmaceuticals Inc in their top 10 stock positions was flat from 0 to 0 for the same number . Sold All: 2 Reduced: 11 Increased: 8 New Position: 4.

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company has market cap of $28.58 million. The firm develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment. It currently has negative earnings. It is also developing NAV5001, an Iodine-123 labeled single photon emission computed tomography imaging agent that is used as an aid in the diagnosis of Parkinsons disease and other movement disorders with potential use as a diagnostic aid in dementia; diagnostic substances, including technetium 99m tilmanocept and other diagnostic applications; and therapeutic development programs, such as therapeutic applications of its Manocept platform, as well as various development programs and therapeutics.

The stock increased 0.69% or $0.0012 during the last trading session, reaching $0.1748. About 194,924 shares traded. Navidea Biopharmaceuticals, Inc (NYSEMKT:NAVB) has declined 44.98% since September 8, 2017 and is downtrending. It has underperformed by 57.55% the S&P500.

Lifeplan Financial Group Inc holds 0.01% of its portfolio in Navidea Biopharmaceuticals, Inc for 28,810 shares. Advisory Services Network Llc owns 5,000 shares or 0% of their US portfolio. Moreover, Ameriprise Financial Inc has 0% invested in the company for 13,600 shares. The California-based Bailard Inc. has invested 0% in the stock. Bank Of America Corp De, a North Carolina-based fund reported 37,503 shares.

Navidea Biopharmaceuticals, Inc (NYSEAMERICAN:NAVB) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.